AstraZeneca (NYSE:AZN) has been given a $40.00 price objective by stock analysts at BMO Capital Markets in a research note issued on Tuesday. The firm currently has a “buy” rating on the stock. BMO Capital Markets’ price target suggests a potential upside of 19.05% from the stock’s current price.
A number of other equities analysts have also weighed in on the stock. Leerink Swann lifted their price objective on shares of AstraZeneca from $36.00 to $38.00 and gave the company a “market perform” rating in a research report on Tuesday, February 6th. Sanford C. Bernstein lifted their price objective on shares of AstraZeneca from $40.00 to $42.00 and gave the company an “outperform” rating in a research report on Monday, February 5th. ValuEngine upgraded shares of AstraZeneca from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 3rd. Zacks Investment Research upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Monday, January 22nd. Finally, JPMorgan Chase & Co. upgraded shares of AstraZeneca from a “neutral” rating to an “overweight” rating in a research report on Friday, December 29th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $35.48.
AstraZeneca (NYSE AZN) traded down $0.33 during trading hours on Tuesday, reaching $33.60. 1,117,885 shares of the company were exchanged, compared to its average volume of 4,378,436. AstraZeneca has a 1 year low of $28.43 and a 1 year high of $36.70. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.93. The stock has a market cap of $83,790.00, a price-to-earnings ratio of 28.46, a price-to-earnings-growth ratio of 2.05 and a beta of 0.74.
AstraZeneca (NYSE:AZN) last posted its quarterly earnings data on Friday, February 2nd. The company reported $1.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.86. AstraZeneca had a net margin of 13.36% and a return on equity of 34.74%. The firm had revenue of $5.78 billion for the quarter, compared to analyst estimates of $5.49 billion. During the same period last year, the firm posted $1.21 EPS. AstraZeneca’s quarterly revenue was up 3.4% on a year-over-year basis. equities research analysts anticipate that AstraZeneca will post 1.67 earnings per share for the current year.
Several large investors have recently added to or reduced their stakes in the company. Delek Group Ltd. acquired a new position in shares of AstraZeneca during the 4th quarter worth $4,453,000. Sawtooth Solutions LLC raised its stake in shares of AstraZeneca by 235.0% during the 4th quarter. Sawtooth Solutions LLC now owns 25,614 shares of the company’s stock worth $888,000 after buying an additional 17,969 shares during the last quarter. We Are One Seven LLC acquired a new position in shares of AstraZeneca during the 4th quarter worth $621,000. Meitav Dash Investments Ltd. acquired a new position in shares of AstraZeneca during the 4th quarter worth $341,000. Finally, BB&T Investment Services Inc. raised its stake in shares of AstraZeneca by 21.2% during the 4th quarter. BB&T Investment Services Inc. now owns 28,035 shares of the company’s stock worth $964,000 after buying an additional 4,899 shares during the last quarter. 14.91% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This story was originally posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://www.thelincolnianonline.com/2018/02/20/astrazeneca-azn-pt-set-at-40-00-by-bmo-capital-markets.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.